Further investigation into the synergistic effects of Rb and p53, MYC and PTEN, and WNT and AR in prostate cancer, as well as the identification of common downstream target genes among these interacting genes or pathways, could lead to the discovery of novel targeted therapies. This evidence concerns the gene AR and Familial prostate cancer.